Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
Identically designed RCTs (both n=358) found an improved remission rate for etrolizumab vs placebo at week 10 in HIBISCUS I (19.4% vs 6.9%, p=0.17), but not in HIBISCUS II (18.2% vs 11.1%, p=0.17). In the pooled analysis, etrolizumab had similar numerical results to adalimumab.
Source:
Lancet Gastroenterology and Hepatology
SPS commentary:
Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody currently under investigation.
Three other trials of etrolizumab have also been published in this journal:
A commentary summarises the results and provides some context and implications of this evidence.